Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Neolife S.A. is a dynamic player in the field of healthcare and wellness solutions. The company is primarily involved in providing innovative preventive healthcare services that align with growing global trends towards proactive health management. Neolife operates through a network of advanced medical centers that offer personalized healthcare programs emphasizing early diagnosis, prevention, and personalized medicine. This approach caters to the increasing consumer demand for longevity and improved quality of life in the healthcare sector. Neolife's services are particularly significant in today's healthcare landscape as they intersect critical sectors such as biotechnology, medical technology, and lifestyle management. By focusing on prevention rather than treatment, Neolife plays a crucial role in transforming traditional healthcare models, contributing to reduced long-term healthcare costs and enhanced patient outcomes. In the financial market, Neolife S.A. represents an opportunity for stakeholders interested in the sustainable and forward-thinking sectors of healthcare. As populations continue to age and seek more comprehensive health solutions, companies like Neolife S.A. stand at the forefront, driving both innovation and accessibility in preventive medicine.
The business is unprofitable at the operating level (-1.28% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue growth slowed to 2.8%, essentially flat. Margins also contracted 4.9pp. This is a business that needs a catalyst.
ROIC dropped from 7.20% to -2.22%, capital efficiency is deteriorating. Operating margin contracted 4.9pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
€13M
▲ +2.8% YoY
Net Income (TTM)
-€117K
▼ -124.7% YoY
Op. Margin
-1.28%
▼ -4.9pp YoY
ROIC
-2.22%
▼ -9.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€612K
Op. Cash Flow (TTM)
€612K
Net Debt
-€864K
Net Cash Position
Cash & Equiv.
€1M
3Y CAGR: -1.0%
Continue Research